Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

K. Choueiri, Toni; J. Motzer, Robert; I. Rini, Brian; B.A.G. Haanen, John; T. Campbell, Matthew; Venugopal, B.; Kollmannsberger, Christian; Gravis, Gwénaëlle; Uemura, Mamoru; Lee, J.L.; Grimm, Marc‐Oliver; Gurney, Howard; Schmidinger, Manuela; Larkin, James; B. Atkins, Michael; K. Pal, Sumanta; Wang, J.; Mariani, Mariangela; Krishnaswami, S.; Cislo, Paul; Chudnovsky, A.; Fowst, Camilla; Huang, Bo; di Pietro, Alessandra; Albigès, Laurence

doi:10.1016/j.annonc.2020.04.010

Public

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

Published in Annals of Oncology • Apr 24, 2020

Authors:

Toni K. Choueiri

Robert J. Motzer

Brian I. Rini

Abstract

BACKGROUND: The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma (aRCC). We report updated efficacy data from the second interim analysis. PATIENT...

Subject

Medicine

Axitinib

Sunitinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!